Leiomyosarcomas

Clinical presentation

Lisa Barrie Schwartz, Michael Peter Diamond, Peter E. Schwartz

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Objective: The ability to preoperatively distinguish benign from malignant myomas is increasingly important because of the availability of more conservative approaches to management of patients with benign uterine enlargement who wish to preserve fertility. Such therapies include observation, medical treatment with gonadotropin-releasing hormone analogs, and hysteroscopic resection of submucosal leiomyomas, in view of these options, this study was undertaken to identify characteristic features of leiomyosarcomas that may preoperatively distinguish benign from malignant myomas. Study Design: The 10-year experience with 21 patients with uterine leiomyosarcomas at Yale-New Haven Hospital was retrospectively reviewed. Results: Leiomyosarcomas were both broad-based and pedunculated and had no preferential uterine location. In 95% of the uterine specimens the leiomyosarcoma was either the largest or the only mass. The leiomyosarcoma was limited to one mass in all patients but one. Conclusion: We recommend that the largest myoma be monitored most closely during conservative management of a uterus containing leiomyomas.

Original languageEnglish (US)
Pages (from-to)180-183
Number of pages4
JournalAmerican Journal of Obstetrics and Gynecology
Volume168
Issue number1
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Leiomyosarcoma
Myoma
Leiomyoma
Gonadotropin-Releasing Hormone
Uterus
Fertility
Observation
Therapeutics

Keywords

  • Myoma
  • gonadotropin-releasing hormone analogs
  • leiomyosarcoma

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Leiomyosarcomas : Clinical presentation. / Schwartz, Lisa Barrie; Diamond, Michael Peter; Schwartz, Peter E.

In: American Journal of Obstetrics and Gynecology, Vol. 168, No. 1, 01.01.1993, p. 180-183.

Research output: Contribution to journalArticle

Schwartz, Lisa Barrie ; Diamond, Michael Peter ; Schwartz, Peter E. / Leiomyosarcomas : Clinical presentation. In: American Journal of Obstetrics and Gynecology. 1993 ; Vol. 168, No. 1. pp. 180-183.
@article{9428110f45964c9bac645aee6f98c571,
title = "Leiomyosarcomas: Clinical presentation",
abstract = "Objective: The ability to preoperatively distinguish benign from malignant myomas is increasingly important because of the availability of more conservative approaches to management of patients with benign uterine enlargement who wish to preserve fertility. Such therapies include observation, medical treatment with gonadotropin-releasing hormone analogs, and hysteroscopic resection of submucosal leiomyomas, in view of these options, this study was undertaken to identify characteristic features of leiomyosarcomas that may preoperatively distinguish benign from malignant myomas. Study Design: The 10-year experience with 21 patients with uterine leiomyosarcomas at Yale-New Haven Hospital was retrospectively reviewed. Results: Leiomyosarcomas were both broad-based and pedunculated and had no preferential uterine location. In 95{\%} of the uterine specimens the leiomyosarcoma was either the largest or the only mass. The leiomyosarcoma was limited to one mass in all patients but one. Conclusion: We recommend that the largest myoma be monitored most closely during conservative management of a uterus containing leiomyomas.",
keywords = "Myoma, gonadotropin-releasing hormone analogs, leiomyosarcoma",
author = "Schwartz, {Lisa Barrie} and Diamond, {Michael Peter} and Schwartz, {Peter E.}",
year = "1993",
month = "1",
day = "1",
doi = "10.1016/S0002-9378(12)90910-2",
language = "English (US)",
volume = "168",
pages = "180--183",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Leiomyosarcomas

T2 - Clinical presentation

AU - Schwartz, Lisa Barrie

AU - Diamond, Michael Peter

AU - Schwartz, Peter E.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Objective: The ability to preoperatively distinguish benign from malignant myomas is increasingly important because of the availability of more conservative approaches to management of patients with benign uterine enlargement who wish to preserve fertility. Such therapies include observation, medical treatment with gonadotropin-releasing hormone analogs, and hysteroscopic resection of submucosal leiomyomas, in view of these options, this study was undertaken to identify characteristic features of leiomyosarcomas that may preoperatively distinguish benign from malignant myomas. Study Design: The 10-year experience with 21 patients with uterine leiomyosarcomas at Yale-New Haven Hospital was retrospectively reviewed. Results: Leiomyosarcomas were both broad-based and pedunculated and had no preferential uterine location. In 95% of the uterine specimens the leiomyosarcoma was either the largest or the only mass. The leiomyosarcoma was limited to one mass in all patients but one. Conclusion: We recommend that the largest myoma be monitored most closely during conservative management of a uterus containing leiomyomas.

AB - Objective: The ability to preoperatively distinguish benign from malignant myomas is increasingly important because of the availability of more conservative approaches to management of patients with benign uterine enlargement who wish to preserve fertility. Such therapies include observation, medical treatment with gonadotropin-releasing hormone analogs, and hysteroscopic resection of submucosal leiomyomas, in view of these options, this study was undertaken to identify characteristic features of leiomyosarcomas that may preoperatively distinguish benign from malignant myomas. Study Design: The 10-year experience with 21 patients with uterine leiomyosarcomas at Yale-New Haven Hospital was retrospectively reviewed. Results: Leiomyosarcomas were both broad-based and pedunculated and had no preferential uterine location. In 95% of the uterine specimens the leiomyosarcoma was either the largest or the only mass. The leiomyosarcoma was limited to one mass in all patients but one. Conclusion: We recommend that the largest myoma be monitored most closely during conservative management of a uterus containing leiomyomas.

KW - Myoma

KW - gonadotropin-releasing hormone analogs

KW - leiomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0027411957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027411957&partnerID=8YFLogxK

U2 - 10.1016/S0002-9378(12)90910-2

DO - 10.1016/S0002-9378(12)90910-2

M3 - Article

VL - 168

SP - 180

EP - 183

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 1

ER -